Neurodegenerative focus Neuraly operates in the neurodegenerative space (PD, AD, MS), presenting opportunities to partner on imaging, biomarkers, and novel therapeutics that align with existing programs and patient populations.

Clinical-stage readiness As a clinical-stage biotech with ongoing partnerships (example: Enigma Biomedical) and a funded Series A history, Neuraly is positioned for collaboration on co-development, translational studies, and strategic financing discussions.

Imaging collaboration Neuraly’s development of PET imaging tracers like PMI04 opens doors for diagnostic imaging partnerships, contract research, and pharmacodynamic readouts to de-risk clinical programs.

Financing momentum With a total funding of around $36M and reported revenue in the $10M–$25M range, Neuraly demonstrates financial scale and potential for milestone-driven partnerships and vendor collaborations.

Growth-ready capabilities A lean team (11–50 employees) supported by a tech stack and digital presence indicates agility for strategic alliances, CRO/CMO collaborations, and scalable manufacturing or gene therapy partnerships as programs advance.